Biotech Stock Plummets as Lung Cancer Trial Hits Roadblock
A significant blow has struck Immutep Ltd (ASX:IMM), a biotechnology firm, with its share price experiencing a dramatic nosedive on Friday. The company effectively shelved its lead candidate for treating lung cancer, a development that often spells considerable trouble for biotechs – a sector known for its speculative investment appeal.
This abrupt downturn saw Immutep’s share price plummet by a staggering 88% within a single trading session, falling to a mere 4.6 cents per share (cps) shortly after the market opened. This starkly contrasts with its closing price of 40 cps on Thursday, pushing Immutep’s year-to-date performance into a deep negative territory of -88%. Consequently, the company’s market capitalisation has shrunk to $68 million. While trading volume surged, the average liquidity has now settled at a more substantial level, though the direction of this increased activity is clearly not in the company’s favour.
Before Friday’s dramatic fall, Immutep had maintained a relatively quiet profile. However, by 1:20 PM Sydney time on Friday, a colossal 332.4 million shares had changed hands, representing a total value of $11.5 million. This is a massive jump from the average volume of just 1.8 million shares observed over the preceding four weeks. It’s worth noting that even $11 million in daily turnover is not particularly large when considering the company has 1.5 billion shares on issue. However, for the biotech industry, such figures are not entirely uncommon, as the journey from initial research to regulatory approval from bodies like the TGA (Therapeutic Goods Administration) or FDA (Food and Drug Administration) is a notoriously long and arduous one.
Discontinuation of Promising Trial Sparks Investor Exodus
The primary catalyst for this sharp decline was the announcement regarding the company’s ongoing trial of its flagship candidate, TACTI-004. Immutep disclosed pre-market on Friday that “Based on its review of the available safety and efficacy data, the [reviewing committee] recommended that the trial be discontinued for futility.”
The gravity of this situation is amplified by the fact that this was a Phase III trial. Phase III trials are considered the ultimate litmus test for drug development, representing the make-or-break stage for ambitious pharmaceutical endeavours. The recommendation to discontinue the trial due to futility has evidently spooked investors, leading them to withdraw their capital rather than holding out hope for a potential recovery.
A Long Road Ahead for Lung Cancer Patients and Investors
Such a setback suggests that any potential path forward for this particular candidate, or indeed for Immutep’s lung cancer treatment ambitions involving TACTI-004, could be a protracted one. Experts estimate that the timeline for any significant progress or a new strategic direction could extend to at least half a decade. This duration is unfortunately comparable to the time some individuals suffering from lung cancer may have to live, highlighting the critical nature of progress in this field.
Immutep’s stock (IMM) was last trading at 4.6 cents per share following the announcement.
The information presented here is for informational purposes only and should not be construed as investment advice. Investors are strongly encouraged to conduct their own thorough research and seek guidance from a qualified financial advisor before making any investment decisions.
